Sphingosine-1-phosphate ameliorates the cardiac hypertrophic response through inhibiting the activity of histone deacetylase-2

Yan,Hui; Yi,Shaowei; Zhuang,Hang; Wu,Lujin; Wang,Dao  Wen; Jiang,Jiangang

doi:10.3892/ijmm.2017.3325

Sphingosine-1-phosphate ameliorates the cardiac hypertrophic response through inhibiting the activity of histone deacetylase-2

Authors:
- Hui Yan
- Shaowei Yi
- Hang Zhuang
- Lujin Wu
- Dao Wen Wang
- Jiangang Jiang
View Affiliations

Affiliations: Department of Internal Medicine and Institute of Hypertension, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: December 15, 2017 https://doi.org/10.3892/ijmm.2017.3325
Pages: 1704-1714

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibition of histone deacetylase-2 (HDAC2), which is a prohypertrophic factor in the heart, can functionally attenuate cardiac hypertrophy. The present study aimed to investigate whether sphingosine‑1‑phosphate (S1P), which has recently been reported to suppress HDAC2 activity, could ameliorate the cardiac hypertrophic response and improve cardiac function in mice with transverse aortic constriction (TAC), as well as to determine the underlying mechanisms. Briefly, 8‑week‑old male C57BL/6 mice were randomly divided into sham, TAC and TAC + S1P groups; the results indicated that S1P treatment attenuated TAC‑induced cardiac dysfunction. In addition, heart size and the expression levels of fetal cardiac genes were reduced in the TAC + S1P group compared with in the TAC group. Furthermore, in cultured H9c2 cells exposed to phenylephrine, S1P was revealed to decrease cardiomyocyte size and the exaggerated expression of fetal cardiac genes. The present study also demonstrated that S1P had no effect on HDAC2 expression, but it did suppress its activity and increase acetylation of histone H3 in vivo and in vitro. Krüppel‑like factor 4 (KLF4) is an antihypertrophic transcriptional regulator, which mediates HDAC inhibitor‑induced prevention of cardiac hypertrophy; in the present study, KLF4 was upregulated by S1P. Finally, the results indicated that S1P receptor 2 (S1PR2) may be involved in the antihypertrophic effects, whereas the suppressive effects of S1P on HDAC2 activity were independent of S1PR2. In conclusion, the present study demonstrated that S1P treatment may ameliorate the cardiac hypertrophic response, which may be partly mediated by the suppression of HDAC2 activity and the upregulation of KLF4; it was suggested that S1PR2 may also be involved. Therefore, S1P may be considered a potential therapy for the treatment of heart diseases caused by cardiac hypertrophy.

View Figures

View References

1	Eom GH and Kook H: Posttranslational modifications of histone deacetylases: Implications for cardiovascular diseases. Pharmacol Ther. 143:168–180. 2014. View Article : Google Scholar : PubMed/NCBI
2	Frey N and Olson EN: Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol. 65:45–79. 2003. View Article : Google Scholar : PubMed/NCBI
3	Chang L, Kiriazis H, Gao XM, Du XJ and El-Osta A: Cardiac genes show contextual SWI/SNF interactions with distinguishable gene activities. Epigenetics. 6:760–768. 2011. View Article : Google Scholar : PubMed/NCBI
4	Eom GH and Kook H: Role of histone deacetylase 2 and its post-translational modifications in cardiac hypertrophy. BMB Rep. 48:131–138. 2015. View Article : Google Scholar :
5	Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, et al: Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med. 13:324–331. 2007. View Article : Google Scholar : PubMed/NCBI
6	Kee HJ and Kook H: Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J Biomed Biotechnol. 2011:9283262011. View Article : Google Scholar
7	Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, et al: Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 113:51–59. 2006. View Article : Google Scholar
8	Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN and Hill JA: Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation. 113:2579–2588. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kee HJ and Kook H: Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J Mol Cell Cardiol. 47:770–780. 2009. View Article : Google Scholar : PubMed/NCBI
10	Takuwa Y, Okamoto Y, Yoshioka K and Takuwa N: Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta. 1781:483–488. 2008. View Article : Google Scholar : PubMed/NCBI
11	Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, et al: Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 325:1254–1257. 2009. View Article : Google Scholar : PubMed/NCBI
12	Means CK and Brown JH: Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res. 82:193–200. 2009. View Article : Google Scholar : PubMed/NCBI
13	National Research Council (US) Committee for the Update of the Guide for the Care and use of Laboratory Animals. Washington (DC): National Academies Press (US); 2011
14	Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y and Kass DA: Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 11:214–222. 2005. View Article : Google Scholar : PubMed/NCBI
15	Liu W, Zi M, Tsui H, Chowdhury SK, Zeef L, Meng QJ, Travis M, Prehar S, Berry A, Hanley NA, et al: A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAt (nuclear factor of activated T-cells) signaling and periostin. Circ Heart Fail. 6:833–844. 2013. View Article : Google Scholar : PubMed/NCBI
16	Cingolani OH, Yang XP, Cavasin MA and Carretero OA: Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension. 41:249–254. 2003. View Article : Google Scholar : PubMed/NCBI
17	Ma H, Gong H, Chen Z, Liang Y, Yuan J, Zhang G, Wu J, Ye Y, Yang C, Nakai A, et al: Association of Stat3 with HSF1 plays a critical role in G-CSF-induced cardio-protection against ischemia/reperfusion injury. J Mol Cell Cardiol. 52:1282–1290. 2012. View Article : Google Scholar : PubMed/NCBI
18	Dolber PC, Bauman RP, Rembert JC and Greenfield JC Jr: Regional changes in myocyte structure in model of canine right atrial hypertrophy. Am J Physiol. 267:H1279–H1287. 1994.PubMed/NCBI
19	Sag CM, Santos CX and Shah AM: Redox regulation of cardiac hypertrophy. J Mol Cell Cardiol. 73:103–111. 2014. View Article : Google Scholar : PubMed/NCBI
20	Knapp M: Cardioprotective role of sphingosine-1-phosphate. J Physiol Pharmacol. 62:601–607. 2011.
21	Karliner JS, Honbo N, Summers K, Gray MO and Goetzl EJ: The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 33:1713–1717. 2001. View Article : Google Scholar : PubMed/NCBI
22	Lecour S, Smith RM, Woodward B, Opie LH, Rochette L and Sack MN: Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 34:509–518. 2002. View Article : Google Scholar : PubMed/NCBI
23	Alvarez SE, Milstien S and Spiegel S: Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab. 18:300–307. 2007. View Article : Google Scholar : PubMed/NCBI
24	Fyrst H and Saba JD: An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol. 6:489–497. 2010. View Article : Google Scholar : PubMed/NCBI
25	Strub GM, Maceyka M, Hait NC, Milstien S and Spiegel S: Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol. 688:141–155. 2010. View Article : Google Scholar : PubMed/NCBI
26	Spiegel S and Milstien S: Functions of a new family of sphin-gosine-1-phosphate receptors. Biochim Biophys Acta. 1484:107–116. 2000. View Article : Google Scholar : PubMed/NCBI
27	Wendler CC and Rivkees SA: Sphingosine-1-phosphate inhibits cell migration and endothelial to mesenchymal cell transformation during cardiac development. Dev Biol. 291:264–277. 2006. View Article : Google Scholar : PubMed/NCBI
28	Seto E and Yoshida M: Erasers of histone acetylation: The histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 6:a0187132014. View Article : Google Scholar : PubMed/NCBI
29	Sekiguchi K, Yokoyama T, Kurabayashi M, Okajima F and Nagai R: Sphingosylphosphorylcholine induces a hypertrophic growth response through the mitogen-activated protein kinase signaling cascade in rat neonatal cardiac myocytes. Circ Res. 85:1000–1008. 1999. View Article : Google Scholar : PubMed/NCBI
30	Robert P, Tsui P, Laville MP, Livi GP, Sarau HM, Bril A and Berrebi-Bertrand I: EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol. 33:1589–1606. 2001. View Article : Google Scholar : PubMed/NCBI
31	Wei L: Lysophospholipid signaling in cardiac myocyte hypertrophy. J Mol Cell Cardiol. 36:465–468. 2004. View Article : Google Scholar : PubMed/NCBI
32	Nguyen-Tran DH, Hait NC, Sperber H, Qi J, Fischer K, Ieronimakis N, Pantoja M, Hays A, Allegood J, Reyes M, et al: Molecular mechanism of sphingosine-1-phosphate action in Duchenne muscular dystrophy. Dis Model Mech. 7:41–54. 2014. View Article : Google Scholar :
33	Nagahashi M, Takabe K, Liu R, Peng K, Wang X, Wang Y, Hait NC, Wang X, Allegood JC, Yamada A, et al: Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology. 61:1216–1226. 2015. View Article : Google Scholar :
34	Pearson R, Fleetwood J, Eaton S, Crossley M and Bao S: Krüppel-like transcription factors: A functional family. Int J Biochem Cell Biol. 40:1996–2001. 2008. View Article : Google Scholar
35	Yoshida T, Yamashita M, Horimai C and Hayashi M: Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity. J Biol Chem. 289:26107–26118. 2014. View Article : Google Scholar : PubMed/NCBI
36	Liao X, Haldar SM, Lu Y, Jeyaraj D, Paruchuri K, Nahori M, Cui Y, Kaestner KH and Jain MK: Krüppel-like factor 4 regulates pressure-induced cardiac hypertrophy. J Mol Cell Cardiol. 49:334–338. 2010. View Article : Google Scholar : PubMed/NCBI